# A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

> **NCT06561425** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 130 (actual)

## Conditions studied

- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell

## Interventions

- **GENETIC:** GLPG5101

## Key facts

- **NCT ID:** NCT06561425
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2029-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561425, "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06561425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*